Sociedad Americana de Hirudoterapia

Linear Peptides Containing d-Leucine with Neuroprotective Activities from the LeechWhitman

Research article published in Journal of natural products (2019)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Desarrollo de fármacosZhang ZY et al. · Journal of natural products, 2019

Abstract

Three new linear peptides containing d-leucine, named whitmantides A-C (1-3), were isolated from the dried whole bodies of Whitmania pigra Whitman. Their structures with absolute configurations were elucidated by Edman degradation, mass spectrometry, Marfey's analysis, and solid-phase synthesis. It is the first time that peptides containing d-amino acid in leeches were discovered. Compounds 1-3 displayed neuroprotective activities against oxygen-glucose deprivation/reperfusion injury on Neuro-2a cells. In addition, ex vivo serum stability tests showed that 1-3 were resistant to protease degradation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsLeechesLeucineNeuroprotective AgentsPeptides

Resumen

Three new linear peptides containing d-leucine, named whitmantides A-C (-), were isolated from the dried whole bodies ofWhitman.

Por qué esto importa para la hirudoterapia

This study isolated three new linear peptides containing d-leucine, named whitmantides A–C, from dried whole bodies of the leech Whitmania pigra, marking the first reported discovery of d-amino-acid-containing peptides in leeches. Structures were determined by Edman degradation, mass spectrometry, Marfey's analysis, and solid-phase synthesis. The compounds showed neuroprotective activity against oxygen-glucose deprivation/reperfusion injury in Neuro-2a cells and resisted protease degradation in ex vivo serum stability tests. For ASH's domain, this is a directly relevant characterization of novel bioactive peptides from a leech source with potential neuroprotective application. The caveat is that findings are preclinical and limited to cell-based and serum-stability assays, with no in-vivo or clinical evidence.

Citación

Linear Peptides Containing d-Leucine with Neuroprotective Activities from the LeechWhitman

Zhang ZY et al. · Journal of natural products, 2019

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.